Related Experiment Video
Updated: Mar 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Atrial Fibrillation: The New Epidemic of the Ageing World
Wilbert S Aronow1, Maciej Banach1
1Cardiology Division, Department of Medicine, New York Medical College, Valhalla, New York and the Department of Molecular Cardionephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
Insights
Atrial fibrillation (AF) management focuses on rate control and stroke prevention. Treatments include cardioversion, medications, pacemakers, and anticoagulation with warfarin or aspirin.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) prevalence increases with age, leading to higher mortality, stroke, and coronary events.
- Rapid ventricular rates in AF can cause tachycardia-related cardiomyopathy.
Purpose of the Study:
- To outline current management strategies for atrial fibrillation (AF).
- To detail treatment options for rate control and stroke prevention in AF patients.
Main Methods:
- Review of established guidelines and clinical practices for AF management.
- Discussion of pharmacological and non-pharmacological interventions.
Main Results:
- Immediate DC cardioversion is indicated for AF with acute myocardial infarction, ischemia, hypotension, heart failure, or syncope.
- Rate control can be achieved with beta blockers, diltiazem, or verapamil; amiodarone for refractory cases.
- Anticoagulation with warfarin (INR 2.0-3.0) is recommended for high-stroke-risk patients; aspirin for low-risk or contraindications.
- Pacemakers are indicated for symptomatic bradycardia or pauses in AF.
Conclusions:
- AF management requires individualized strategies balancing rate control, rhythm control, and stroke prevention.
- Warfarin and aspirin are key for stroke risk reduction in AF.
- Cardioversion and pacing offer important therapeutic options for specific AF presentations.
Abstract:
The prevalence of atrial fibrillation (AF) increases with age. As the population ages, the burden of AF increases. AF is associated with an increased incidence of mortality, stroke, and coronary events compared to sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current (DC) cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, diltiazem, or verapamil may be administered to reduce immediately a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nondrug therapies should be performed in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. Paroxysmal AF associated with the tachycardia-bradycardia syndrome should be treated with a permanent pacemaker in combination with drugs. A permanent pacemaker should be implanted in patients with AF and symptoms such as dizziness or syncope associated with ventricular pauses greater than 3 seconds which are not drug-induced. Elective DC cardioversion has a higher success rate and a lower incidence of cardiac adverse effects than does medical cardioversion in converting AF to sinus rhythm. Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective DC or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm. Many cardiologists prefer, especially in elderly patients , ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs. Patients with chronic or paroxysmal AF at high risk for stroke should be treated with long-term warfarin to achieve an International Normalized Ratio of 2.0 to 3.0. Patients with AF at low risk for stroke or with contraindications to warfarin should be treated with aspirin 325 mg daily.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Rheumatic Heart Disease I: Introduction
Dysrhythmias VI: Management of Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Heart Failure II: Pathophysiology
Dysrhythmias II: Classification of Tachyarrhythmias

